Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcellx Inc (ACLX)

Arcellx Inc (ACLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,724,681
  • Shares Outstanding, K 55,107
  • Annual Sales, $ 107,940 K
  • Annual Income, $ -107,350 K
  • EBIT $ -191 M
  • EBITDA $ -201 M
  • 60-Month Beta 0.28
  • Price/Sales 36.22
  • Price/Cash Flow N/A
  • Price/Book 9.37

Options Overview Details

View History
  • Implied Volatility 54.99% ( +4.59%)
  • Historical Volatility 30.72%
  • IV Percentile 51%
  • IV Rank 20.82%
  • IV High 105.37% on 11/04/24
  • IV Low 41.75% on 02/27/25
  • Put/Call Vol Ratio 40.00
  • Today's Volume 82
  • Volume Avg (30-Day) 125
  • Put/Call OI Ratio 2.74
  • Today's Open Interest 12,858
  • Open Int (30-Day) 13,481

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -1.03
  • Number of Estimates 7
  • High Estimate -0.77
  • Low Estimate -1.27
  • Prior Year -0.51
  • Growth Rate Est. (year over year) -101.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.92 +10.95%
on 06/20/25
71.57 -5.57%
on 07/18/25
+3.77 (+5.91%)
since 06/18/25
3-Month
47.86 +41.22%
on 05/07/25
71.57 -5.57%
on 07/18/25
+5.57 (+8.98%)
since 04/17/25
52-Week
47.86 +41.22%
on 05/07/25
107.37 -37.05%
on 11/12/24
+5.35 (+8.60%)
since 07/18/24

Most Recent Stories

More News
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs

/CNW/ -- Equity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is...

ONCY : 1.2700 (-3.79%)
ACLX : 67.59 (-4.74%)
TCRX : 1.8200 (-3.70%)
ONC.TO : 1.73 (-2.81%)
AKYA : 1.2900 (-5.15%)
QTRX : 5.37 (-2.54%)
Stocks Under Pressure from Higher Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is down -0.13%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.12%. Stocks today are slightly...

APO : 152.00 (-2.60%)
BABA : 120.23 (+2.50%)
NVDA : 172.41 (-0.34%)
IPG : 24.18 (+0.21%)
OMC : 71.06 (+0.28%)
$SPX : 6,296.79 (-0.01%)
BIOA : 4.63 (-3.54%)
SMCI : 51.77 (-1.86%)
BIDU : 87.81 (+0.34%)
FTV : 50.53 (-1.44%)
$IUXX : 23,065.47 (-0.05%)
WDAY : 233.06 (+0.94%)
Insider Sale: Director at $ACLX (ACLX) Sells 300 Shares

Kavita Patel, a director at $ACLX ($ACLX), sold 300 shares of the company on 12-03-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 100.0% of their shares....

ACLX : 67.59 (-4.74%)
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

/CNW/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase...

ONCY : 1.2700 (-3.79%)
ACLX : 67.59 (-4.74%)
ONC.TO : 1.73 (-2.81%)
GTHX : 7.15 (unch)
HALO : 56.45 (-2.34%)
SNY : 48.32 (-0.68%)
2 Potential Stocks to Buy From Barchart’s ‘Death Cross’ Indicator

While a security’s short-term moving average dipping below its long-term average warrants caution, this dynamic may also be a contrarian indicator.

ACLX : 67.59 (-4.74%)
IRTC : 136.24 (+0.35%)
Chart of the Day: Arcellx - Reimagining Cell Therapy

The Chart of the Day belongs to the immunotherapy company Arcellx (ACLX) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest...

ACLX : 67.59 (-4.74%)
Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results

/PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for...

ACLX : 67.59 (-4.74%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arcellx, Inc. ("Arcellx" or the "Company") (NASDAQ: ACLX). Such investors are...

ACLX : 67.59 (-4.74%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arcellx, Inc. ("Arcellx" or the "Company") (NASDAQ: ACLX). Such investors are...

ACLX : 67.59 (-4.74%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arcellx, Inc. ("Arcellx" or the "Company") (NASDAQ: ACLX). Such investors are...

ACLX : 67.59 (-4.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Arcellx Inc. is a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx Inc. is based in GAITHERSBURG, Md.

See More

Key Turning Points

3rd Resistance Point 75.11
2nd Resistance Point 73.34
1st Resistance Point 70.47
Last Price 67.59
1st Support Level 65.82
2nd Support Level 64.05
3rd Support Level 61.18

See More

52-Week High 107.37
Fibonacci 61.8% 84.64
Fibonacci 50% 77.62
Fibonacci 38.2% 70.59
Last Price 67.59
52-Week Low 47.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar